<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37173771</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>Risk factors for avascular necrosis in patients with systemic lupus erythematosus: a multi-center cohort study of Chinese SLE Treatment and Research Group (CSTAR) Registry XXII.</ArticleTitle><Pagination><StartPage>78</StartPage><MedlinePgn>78</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">78</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-023-03061-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Avascular necrosis is a common organ damage in SLE patients, which can influence patients' life quality. Conflicting results exist in risk factors of AVN in SLE patients. The aim of this study was to illustrate risk factors predicting the occurrence of avascular necrosis (AVN), also known as osteonecrosis, in systemic lupus erythematosus (SLE) patients in Chinese SLE Treatment and Research Group (CSTAR), a multi-center cohort of Chinese SLE patients.</AbstractText><AbstractText Label="METHODS">SLE patients in CSTAR without existing AVN at registration were included. At least two follow-ups and an observation period of no less than 2&#xa0;years for AVN event were required. Univariate and multivariate Cox regression analyses were used to evaluate risk factors for AVN in SLE patients. Coefficient B was transformed to risk score for the development of a risk stratification model.</AbstractText><AbstractText Label="RESULTS">One hundred six (2.59%) of 4091 SLE patients were diagnosed AVN during follow-ups of no less than 2&#xa0;years. Multi-variate Cox regression analysis suggested that SLE onset age&#x2009;&#x2264;&#x2009;30 (HR 1.616, p 0.023), arthritis (HR 1.642, p 0.018), existing organ damage (SDI&#x2009;&#x2265;&#x2009;1) at registration (HR 2.610, p&#x2009;&lt;&#x2009;0.001), positive anti-RNP (HR 1.709, p 0.006), and high glucocorticoid maximum daily dose at registration (HR 1.747, p 0.02) were independent risk factors. A risk stratification system was developed according to the risk factors, and patients were divided into high risk (3-6) and low risk (0-2). The AUC of 0.692 indicated moderate discrimination. The calibration curve in internal validation was drawn.</AbstractText><AbstractText Label="CONCLUSION">Patients with SLE onset age&#x2009;&#x2264;&#x2009;30, arthritis, existing organ damage (SDI&#x2009;&#x2265;&#x2009;1) at registration, positive anti-RNP, and high glucocorticoid maximum daily dose at registration are at high risk for AVN and require attention.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Cheng</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Huang</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Zhen</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Hainan General Hospital, Haikou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Xinwang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yongfu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology Institute of Immunology and Rheumatology Inner Mongolia Key Laboratory of Autoimmunity, The First Affiliated Hospital of Baotou Medical College, Baotou Medical College, Baotou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Zhenbiao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Xijing Hospital Affiliated to the Fourth Military Medical University, Xi'an, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, First Affiliated Hospital of Kunming Medical University, Kunming, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hongbin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical College, Hohhot, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Nanchang University, Nanchang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Jiuliang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Shangzhu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leng</LastName><ForeName>Xiaomei</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tian</LastName><ForeName>Xinping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Mengtao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China. mengtao.li@cstar.org.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Xiaofeng</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science &amp; Technology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, 100730, China. zengxfpumc@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095225" MajorTopicYN="N">East Asian People</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010020" MajorTopicYN="Y">Osteonecrosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001168" MajorTopicYN="Y">Arthritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Avascular necrosis</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">Risk stratification</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>13</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37173771</ArticleId><ArticleId IdType="pmc">PMC10176939</ArticleId><ArticleId IdType="doi">10.1186/s13075-023-03061-3</ArticleId><ArticleId IdType="pii">10.1186/s13075-023-03061-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929&#x2013;939. doi: 10.1056/NEJMra071297.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra071297</ArticleId><ArticleId IdType="pubmed">18305268</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E, et al. The Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol. 2000;27(2):373&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pubmed">10685799</ArticleId></ArticleIdList></Reference><Reference><Citation>Oinuma K, Harada Y, Nawata Y, Takabayashi K, Abe I, Kamikawa K, et al. Osteonecrosis in patients with systemic lupus erythematosus develops very early after starting high dose corticosteroid treatment. Ann Rheum Dis. 2001;60(12):1145&#x2013;1148. doi: 10.1136/ard.60.12.1145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.60.12.1145</ArticleId><ArticleId IdType="pmc">PMC1753447</ArticleId><ArticleId IdType="pubmed">11709458</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayarlioglu M, Yuzbasioglu N, Inanc M, Kamali S, Cefle A, Karaman O, et al. Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus. Rheumatol Int. 2012;32(1):177&#x2013;182. doi: 10.1007/s00296-010-1597-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-010-1597-9</ArticleId><ArticleId IdType="pubmed">20711782</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuroda T, Tanabe N, Wakamatsu A, Takai C, Sato H, Nakatsue T, et al. High triglyceride is a risk factor for silent osteonecrosis of the femoral head in systemic lupus erythematosus. Clin Rheumatol. 2015;34(12):2071&#x2013;2077. doi: 10.1007/s10067-015-3075-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-015-3075-y</ArticleId><ArticleId IdType="pubmed">26384821</ArticleId></ArticleIdList></Reference><Reference><Citation>Vande Berg BC, Malghem J, Lecouvet FE, Devogelaer JP, Maldague B, Houssiau FA. Fat conversion of femoral marrow in glucocorticoid-treated patients: a cross-sectional and longitudinal study with magnetic resonance imaging. Arthritis Rheum. 1999;42(7):1405&#x2013;1411. doi: 10.1002/1529-0131(199907)42:7&lt;1405::AID-ANR14&gt;3.0.CO;2-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199907)42:7&lt;1405::AID-ANR14&gt;3.0.CO;2-W</ArticleId><ArticleId IdType="pubmed">10403268</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima W, Fujioka M, Kubo T, Tamakoshi A, Nagai M, Hirota Y. Nationwide epidemiologic survey of idiopathic osteonecrosis of the femoral head. Clin Orthop Relat Res. 2010;468(10):2715&#x2013;2724. doi: 10.1007/s11999-010-1292-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11999-010-1292-x</ArticleId><ArticleId IdType="pmc">PMC2939331</ArticleId><ArticleId IdType="pubmed">20224959</ArticleId></ArticleIdList></Reference><Reference><Citation>Nevskaya T, Gamble MP, Pope JE. A meta-analysis of avascular necrosis in systemic lupus erythematosus: prevalence and risk factors. Clin Exp Rheumatol. 2017;35(4):700&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">28240590</ArticleId></ArticleIdList></Reference><Reference><Citation>Golder V, Connelly K, Staples M, Morand E, Hoi A. Association of Asian ethnicity with disease activity in SLE: an observational study from the Monash Lupus Clinic. Lupus. 2013;22(13):1425&#x2013;1430. doi: 10.1177/0961203313500547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313500547</ArticleId><ArticleId IdType="pubmed">23942610</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M, Wang Y, Zhao J, Wang Q, Wang Z, Tian X, et al. Chinese SLE Treatment and Research Group (CSTAR) registry 2009&#x2013;2019: major clinical characteristics of Chinese patients with systemic lupus erythematosus. Rheumatol Immunol Res. 2021;2(1):43&#x2013;47. doi: 10.2478/rir-2021-0001.</Citation><ArticleIdList><ArticleId IdType="doi">10.2478/rir-2021-0001</ArticleId><ArticleId IdType="pmc">PMC9524770</ArticleId><ArticleId IdType="pubmed">36467897</ArticleId></ArticleIdList></Reference><Reference><Citation>Faezi ST, Hoseinian AS, Paragomi P, Akbarian M, Esfahanian F, Gharibdoost F, et al. Non-corticosteroid risk factors of symptomatic avascular necrosis of bone in systemic lupus erythematosus: A retrospective case-control study. Mod Rheumatol. 2015;25(4):590&#x2013;594. doi: 10.3109/14397595.2014.987366.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14397595.2014.987366</ArticleId><ArticleId IdType="pubmed">25528860</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura J, Saisu T, Yamashita K, Suzuki C, Kamegaya M, Takahashi K. Age at time of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum. 2010;62(2):609&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pubmed">20112393</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Urowitz MB, Chaudhry-Ahluwalia V, Hallet DC, Cook RJ. Predictive factors for symptomatic osteonecrosis in patients with systemic lupus erythematosus. J Rheumatol. 2001;28(4):761&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pubmed">11327247</ArticleId></ArticleIdList></Reference><Reference><Citation>Mont MA, Pivec R, Banerjee S, Issa K, Elmallah RK, Jones LC. High-dose corticosteroid use and risk of hip osteonecrosis: meta-analysis and systematic literature review. J Arthroplasty. 2015;30(9):1506&#x2013;12 e5. doi: 10.1016/j.arth.2015.03.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arth.2015.03.036</ArticleId><ArticleId IdType="pmc">PMC7127809</ArticleId><ArticleId IdType="pubmed">25900167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallas R, Li J, Petri M. Predictors of osteonecrosis in systemic lupus erythematosus: a prospective cohort study. Arthritis Care Res (Hoboken) 2022;74(7):1122&#x2013;1132. doi: 10.1002/acr.24541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24541</ArticleId><ArticleId IdType="pubmed">33342072</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko K, Chen H, Kaufman M, Sverdlov I, Stein EM, Park-Min KH. Glucocorticoid-induced osteonecrosis in systemic lupus erythematosus patients. Clin Transl Med. 2021;11(10):e526. doi: 10.1002/ctm2.526.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ctm2.526</ArticleId><ArticleId IdType="pmc">PMC8506634</ArticleId><ArticleId IdType="pubmed">34709753</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura J, Ohtori S, Sakamoto M, Chuma A, Abe I, Shimizu K. Development of new osteonecrosis in systemic lupus erythematosus patients in association with long-term corticosteroid therapy after disease recurrence. Clin Exp Rheumatol. 2010;28(1):13&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pubmed">20346232</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghazy AA, Ibrahim AM. Predictors of avascular necrosis in a cohort of Egyptian systemic lupus erythematosus patients: retrospective two centers study. Curr Rheumatol Rev. 2022;18(2):144&#x2013;149. doi: 10.2174/1573397117666210907124242.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573397117666210907124242</ArticleId><ArticleId IdType="pubmed">34493196</ArticleId></ArticleIdList></Reference><Reference><Citation>Prasad R, Ibanez D, Gladman D, Urowitz M. The role of non-corticosteroid related factors in osteonecrosis (ON) in systemic lupus erythematosus: a nested case-control study of inception patients. Lupus. 2007;16(3):157&#x2013;162. doi: 10.1177/0961203306075771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203306075771</ArticleId><ArticleId IdType="pubmed">17432099</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans CE, Cober ND, Dai Z, Stewart DJ, Zhao YY. Endothelial cells in the pathogenesis of pulmonary arterial hypertension. Eur Respir J. 2021;58(3):2003957. doi: 10.1183/13993003.03957-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.03957-2020</ArticleId><ArticleId IdType="pmc">PMC8316496</ArticleId><ArticleId IdType="pubmed">33509961</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J, Yao Z, Xue L, Wang D, Tan Z. The role of immune cells in modulating chronic inflammation and osteonecrosis. Front Immunol. 2022;13:1064245. doi: 10.3389/fimmu.2022.1064245.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1064245</ArticleId><ArticleId IdType="pmc">PMC9792770</ArticleId><ArticleId IdType="pubmed">36582244</ArticleId></ArticleIdList></Reference><Reference><Citation>Long Y, Zhang S, Zhao J, You H, Zhang L, Li J, et al. Risk of osteonecrosis in systemic lupus erythematosus: an 11-year Chinese single-center cohort study. Lupus. 2021;30(9):1459&#x2013;1468. doi: 10.1177/09612033211021166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211021166</ArticleId><ArticleId IdType="pubmed">34082592</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Lau CS, Wong RW. Risk factors for avascular bone necrosis in systemic lupus erythematosus. Br J Rheumatol. 1998;37(8):895&#x2013;900. doi: 10.1093/rheumatology/37.8.895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/37.8.895</ArticleId><ArticleId IdType="pubmed">9734682</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu KK, Xu WD, Pan HF, Zhang M, Ni J, Ge FY, et al. The risk factors of avascular necrosis in patients with systemic lupus erythematosus: a meta-analysis. Inflammation. 2014;37(5):1852&#x2013;1864. doi: 10.1007/s10753-014-9917-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-014-9917-y</ArticleId><ArticleId IdType="pubmed">24862229</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum. 2013;43(3):352&#x2013;361. doi: 10.1016/j.semarthrit.2013.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2013.05.003</ArticleId><ArticleId IdType="pubmed">23786872</ArticleId></ArticleIdList></Reference><Reference><Citation>Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity. 2005;38(1):47&#x2013;54. doi: 10.1080/08916930400022715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08916930400022715</ArticleId><ArticleId IdType="pubmed">15804705</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong J, Wang G, Xu T, Liu R, Yu S, Wang Y, et al. Anti-RNP antibody: a potential novel predictor for osteonecrosis in systemic lupus erythematosus. Front Med (Lausanne) 2022;9:847875. doi: 10.3389/fmed.2022.847875.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.847875</ArticleId><ArticleId IdType="pmc">PMC9035537</ArticleId><ArticleId IdType="pubmed">35479947</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Q, Zhou M, Liu J, Zhang S, Gao F, Lin H, et al. Relationship between osteonecrosis and antiphospholipid antibodies in patients with systemic lupus erythematosus: a systematic review protocol. BMJ Open. 2021;11(7):e046163. doi: 10.1136/bmjopen-2020-046163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-046163</ArticleId><ArticleId IdType="pmc">PMC8728347</ArticleId><ArticleId IdType="pubmed">34301653</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Zheng Z, Zhang K, Zhu P. Osteonecrosis in systemic lupus erythematosus: Systematic insight from the epidemiology, pathogenesis, diagnosis and management. Autoimmun Rev. 2022;21(2):102992. doi: 10.1016/j.autrev.2021.102992.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102992</ArticleId><ArticleId IdType="pubmed">34793961</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>